Find out what happened in the markets today - and why you should care - with the free Daily Brief newsletter.

Amgen is turning heads with its experimental weight-loss drug, MariTide, which promises faster results with fewer doses than existing GLP-1 treatments.

What does this mean?

Competitors like Eli Lilly's Zepbound and Novo Nordisk's Wegovy already boast impressive weight loss outcomes -- 15% and over 22% respectively -- but Amgen is setting its sights on MariTide achieving at least a 20% weight loss, potentially reaching 25%. This goal has sparked market interest, pushing Amgen's stock up by 8% over the past year. However, safety concerns, particularly regarding bone density impact, led to a 9% stock dip. Analysts are keenly awaiting Phase 2 trial data to clarify efficacy and side effect profiles, as prior trials showed a significant 50% dropout due to nausea and vomiting. In response, Amgen claims MariTide presents no bone density issues, positioning it as a formidable player in a market set to exceed $150 billion annually.

The recent 9% drop in Amgen's stock signals investor caution as the market awaits more safety data on MariTide. Phase 2 outcomes could significantly sway market sentiment and Amgen's stock price, contingent on their handling of safety concerns and proof of efficacy. With the obesity drug market expanding rapidly, MariTide stands to gain substantially if it meets safety and effectiveness standards.

The bigger picture: Pharmaceutical giants play the long game.

The competition for leadership in the obesity drug market is heating up, bringing substantial financial stakes. For Amgen, overcoming initial safety issues while hitting efficacy milestones could secure its position in this fast-growing sector. As the global emphasis on health rises, delivering safe, effective weight-loss options will determine success, shaping the future not only for Amgen but the entire pharmaceutical industry.